共 50 条
- [31] Enfortumab vedotin in the treatment of urothelial cancers and beyondFUTURE ONCOLOGY, 2022, 18 (27) : 3067 - 3084Wong, Risa L.Yu, Evan Y.
- [32] Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Friedlander, Terence W.Milowsky, Matthew I.O'Donnell, Peter H.Petrylak, Daniel P.Hoimes, Christopher J.Flaig, Thomas W.Mar, NataliyaMoon, Helen H.McKay, Rana R.Bilen, Mehmet AsimBorchiellini, DelphineIafolla, MarcoCarret, Anne-SophieYu, YaoGuseva, MariaKataria, Ritesh S.Rosenberg, Jonathan E.
- [33] KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Galsky, Matt D.Necchi, AndreaShore, Neal D.Plimack, Elizabeth R.Jia, CalvinSbar, EricMoreno, Blanca HometWitjes, Johannes Alfred
- [34] Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in ContextONCOTARGETS AND THERAPY, 2022, 15 : 1519 - 1529Hoffman-Censits, JeanMaldonado, Laneisha
- [35] Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancerANNALS OF ONCOLOGY, 2020, 31 : S594 - S594Koshkin, V. S.Sun, Y.Osterman, C. K.Natesan, D.Su, C.Lemke, E.Khaki, A. R.Johnson, A.Owens, X.Park, J. J.Basu, A.Barata, P. M. CoelhoDavis, N.Grivas, P.Milowsky, M.Kilari, D.Alva, A.
- [36] Enfortumab Vedotin in Previously Treated Advanced Urothelial CarcinomaNEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1125 - 1135Powles, ThomasRosenberg, Jonathan E.Sonpavde, Guru P.Loriot, YohannDuran, IgnacioLee, Jae-LyunMatsubara, NobuakiVulsteke, ChristofCastellano, DanielWu, ChunzhangCampbell, MaryMatsangou, MariaPetrylak, Daniel P.
- [37] Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?FRONTIERS IN ONCOLOGY, 2023, 13Maiorano, Brigida AnnaCatalano, MartinaMaiello, EvaristoRoviello, Giandomenico
- [38] ABC transporter expression to predict therapeutic effect of enfortumab vedotin in urothelial cancerJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 693 - 693Shimoda, HirokiTakada-Owada, AtsukoKijima, ToshikiKokubun, HidetoshiUematsu, ToshitakaTakei, KoheiNakazato, YoshimasaYashi, MasahiroIshida, KazuyukiKamai, Takao
- [39] First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer PatientsPHARMACEUTICALS, 2023, 16 (03)Vulsteke, ChristofDe Cocker, Laurensde Liano, Alfonso GomezMontesdeoca, CristinaDe Meulenaere, AstridCroes, LieselotDelombaerde, DanielleSzabados, BernadettPowles, Thomas
- [40] Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV103 cohort K.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41O'Donnell, Peter H.Rosenberg, Jonathan E.Hoimes, Christopher J.Petrylak, Daniel P.Milowsky, Matthew I.Mckay, Rana R.Srinivas, SandyFriedlander, Terence W.Ramamurthy, ChethanBilen, Mehmet AsimBurgess, Earle F.Mar, NataliyaMoon, HelenGeynisman, Daniel M.George, SabyCarret, Anne-SophieYu, YaoGuseva, MariaMoreno, Blanca HometFlaig, Thomas W.